Display Settings:

Format

Send to:

Choose Destination
    Expert Opin Drug Saf. 2009 Mar;8(2):145-53.

    Drug safety profile of darbepoetin alfa for anemia of chronic kidney disease.

    Source

    The Ohio State University, 395 W 12th Avenue, Columbus, Ohio 43210, USA. anil.agarwal@osumc.edu

    Abstract

    Anemia of chronic kidney disease due to deficiency of erythropoietin is common and has clinical consequences. Erythropoiesis stimulating agents including darbepoetin alfa (DA) are effective in correcting anemia. DA is generally well tolerated and has side effect profile similar to recombinant human erythropoietin. It has a long half-life permitting infrequent dosing. DA has been tested extensively in preclinical and clinical studies and significant experience has accumulated in clinical practice. Global safety profile of DA must consider recent data indicating worse survival, poor cardiovascular outcomes and thrombotic risks of targeting near normal hemoglobin levels and administering high doses of erythropoiesis stimulating agents. Strategies to achieve and maintain a reasonable, individualized target hemoglobin level with minimal variations in hemoglobin level are needed.

    PMID:
    19309243
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Informa Healthcare

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk